Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study

Clicks: 383
ID: 120028
1997
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
112 patients admitted to hospital with a diagnosis of erysipelas, were randomized to 8 days treatment with prednisolone or placebo in addition to antibiotics. 108 patients received the study drugs and were evaluated for time to cure, which was the primary end-point. The median healing time was signi …
Reference Key
pi1997scandinavianantibiotic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bergkvist PI;Sjöbeck K;;
Journal scandinavian journal of infectious diseases
Year 1997
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9360253
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male middle aged Recurrence Clinical Trial Randomized Controlled Trial Double-Blind Method hospitalization drug therapy combination anti-inflammatory agents / therapeutic use* streptococcal infections / diagnosis penicillins / therapeutic use leukocyte count penicillins / administration & dosage staphylococcal infections / diagnosis erysipelas / drug therapy* anti-inflammatory agents / adverse effects bacteremia / diagnosis staphylococcus aureus / growth & development streptococcus / growth & development p i bergkvist k sjöbeck prednisolone / therapeutic use* pmid:9360253 doi:10.3109/00365549709011834 anti-inflammatory agents / administration & dosage prednisolone / administration & dosage prednisolone / adverse effects staphylococcal infections / blood streptococcal infections / blood

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.